Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients

prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Kaplan-Meier analysis of time to death in patients prescribed celecoxib, rofecoxib,or

non-steroidal anti-inflammatory drugs

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Baseline characteristics of patients with congestive

heart failure prescribed celecoxib,rofecoxib,or

non-steroidal anti-inflammatory drugs (NSAIDs)

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Prescribing characteristics for patients given celecoxib,rofecoxib,or non-steroidal

anti-inflammatory drugs (NSAIDs)

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Kaplan-Meier analysis of time to recurrent congestive heart failure in patients

prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Unadjusted rates of study events in patients

with congestive heart failure who were prescribed celecoxib,rofecoxib,or non-

steroidal anti-inflammatory drugs (NSAIDs)

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Adjusted hazard ratios (95%confidence intervals)

for death and recurrent congestive heart failure,

combined and alone, according to exposure group

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370